Related references
Note: Only part of the references are listed.A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys
Sutada Lotinun et al.
BONE (2010)
Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption
Taina Taube et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee
A. Michael Parfitt et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
Sonia Vallet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Role of decorin in the antimyeloma effects of osteoblasts
Xin Li et al.
BLOOD (2008)
Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell - Depleted SCID mice
Hirokazu Ogino et al.
CLINICAL CANCER RESEARCH (2008)
A soluble activin type IIA receptor induces bone formation and improves skeletal integrity
R. Scott Pearsall et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The activin A-follistatin system: potent regulator of human extracellular matrix mineralization
Marco Eijken et al.
FASEB JOURNAL (2007)
Age-related changes in trabecular architecture differ in female and male C57BL/6J mice
Vaida Glatt et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Inhibin A is an endocrine stimulator of bone mass and strength
Daniel S. Perrien et al.
ENDOCRINOLOGY (2007)
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis
Florence Daubine et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer
Gaetano Leto et al.
CLINICAL & EXPERIMENTAL METASTASIS (2006)
MEKK1 transduces activin signals in keratinocytes to induce actin stress fiber formation and migration
L Zhang et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial
LS Rosen et al.
CANCER (2003)
Multiple myeloma biology: lessons from the 5TMM models
K Vanderkerken et al.
IMMUNOLOGICAL REVIEWS (2003)
Hypoxia is a major stimulator of osteoclast formation and bone resorption
TR Arnett et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2003)
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival
PI Croucher et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Metastasis to bone: Causes, consequences and therapeutic opportunities
GR Mundy
NATURE REVIEWS CANCER (2002)
Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures
D Gaddy-Kurten et al.
ENDOCRINOLOGY (2002)
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
RE Coleman
CANCER TREATMENT REVIEWS (2001)
Activin A is an essential cofactor for osteoclast induction
K Fuller et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma
N Abildgaard et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2000)
Share Paper
